EUCTR2018-003436-74-RO进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-controlled, Three-arm, Parallel Assignment, Multi-Centre, Therapeutic Equivalence Study of Two Fluorouracil 5% Topical Cream Formulations in Adult Patients with Multiple Actinic Keratoses Lesions - ARTE study
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females of any ethnic group, over 18 years of age at the time of signing the informed consent.
- •2. Patients with Fitzpatrick skin type I, II and III
- •3. Patients with at least 5 but no more than 10 clinically typical, visible, discrete actinic keratoses (AKs) lesions on the face or bald scalp with each lesion measuring at least 4 mm
- •in diameter.
- •4. Both male and female patients of child bearing potential must be practicing adequate contraception and female patients of child-bearing potential must not be pregnant or
- •lactating and must have a negative serum pregnancy test at screening and negative urine pregnancy test at randomization.
- •5. Patient is capable of understanding the purposes and risks of the trial, is able to comply with the study requirements and restrictions as listed in the consent form and has given
- •written informed consent
- •6. Patient has not taken and agrees not to take any medication or therapy prohibited by the protocol for the entire study period
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1. Presence of atopic dermatitis, basal cell carcinoma, eczema, psoriasis, rosacea, squamous cell carcinoma, albinism or other confounding skin conditions on the face or bald scalp.
- •2. Patients with lesions that are hyperkeratotic, thicker than 1 mm (a piece of paper) or larger than 9mm or suspicious for squamous cell carcinoma.
- •3. Use within six months prior to screening on the face or bald scalp of 1) chemical peel, 2) dermabrasion, 3) laser abrasion, 4) PUVA (Psoralen plus UltraViolet A) therapy, or 5) UVB therapy.
- •4. Use within one month prior to screening on the face or scalp of 1) cryodestruction or chemodestruction, 2) curettage, 3) photodynamic therapy, 4) surgical excision, 5) topical
- •5-fluorouracil, 6) topical corticosteroids 7) topical diclofenac, 8) topical imiquimod, 9) topical retinoids, or 10) other treatments for actinic keratoses.
- •5. Use within one month prior to screening of 1) immunomodulators or immunosuppressive therapies, 2) interferon, 3) oral corticosteroids 4) cytotoxic drugs or 5) medicines like
- •brivudine, sorivudine, etc. to treat chickenpox or shingles.
- •6. Known allergies to fluorouracil or any excipients in the test product or the RLD.
- •7. The total area of skin with AK needing treatment at a time exceeding 500cm^2 (approx. 23 x 23 cm) or (9 x 9 inches), the size of a dinner plate.
- •8. Known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.
- •9. Any dermatological condition such as scar/wound/tattoo at the application site or in its close vicinity that in the Investigator's opinion may interfere with the evaluation of the
- •patient's AKs.
- •10. Known case of HIV infection.
- •11. A positive hepatitis screen including hepatitis B surface antigen, HCV, HAV and IgM antibodies.
- •12. Clinical evidence of severe, uncontrolled auto-immune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, pulmonary or renal disease.
- •13. Serious psychological illness.
- •14. Significant history (within the past 1 year) of alcohol or drug abuse (unable to control its consumption despite negative consequences).
- •15. Participation in any clinical research study during the 30 day period preceding the current study screening or 5 half-lives of the last intake of the IMP during the previous study
- •whichever is later.
- •16. Medical history which, based on the clinical judgment of the investigator, implies a likelihood of unsuccessful completion of the study.
- •17. Use of sun lamps or sun tanning beds or booths from 1 week prior to screening until End of Study (EoS) visit on Day 42.
- •18. Scheduled elective surgery within 30 days of study.
- •19. Not willing to visit the site without make up on face or neck.
- •20. Patients engaged in occupation requiring prolonged exposure to sunlight/non-ionizing UV radiation.
- •21. Prior treatment with systemic 5-fluorouracil or intended systemic cancer therapy within 6 months of study entry
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate if a new cream of Fluorouracil 5% for treatment of actinic keratoses lesions is equivalent to an existing one that also contains Fluorouracil 5%MedDRA version: 20.0Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersActinic KeratosisEUCTR2018-003436-74-ESIntas Pharmaceuticals Ltd240
已完成
不适用
enzilumab Study in Healthy Korean SubjectsCodes for special purposesKCT0006851Telcon RF Pharmaceuticals20
已完成
不适用
A human study to Investigate the Effect of L.lactis CKDB001 Administration on Liver Aminotransferases in Subjects with Nonalcoholic Fatty Liver DiseaseKCT0007388Chong Kun Dang Bio120
尚未招募
不适用
A Randomized, Double-blinded, Placebo-controlled, Multi-center Phase 2 Study to Explore the Efficacy and Safety of Subcutaneous Injection EG-Myocin Immediately Before and After PCI in Patients with Acute ST-Elevation Myocardial Infarction (STEMI)KCT0004288Eyegene60
招募中
1 期
Trial to evaluate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia PatientsCOVID-19 Pneumonia PatientsMedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862EUCTR2022-001152-42-BGShaperon, Inc.1,134